Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 06 - 04 save search
Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
Published: 2021-06-04 (Crawled : 20:00) - prnewswire.com
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
| Email alert
Add to watchlist
phase 2 results
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 0.38%
H: 1.25%
C: -0.76%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 3.74%
H: 3.11%
C: 2.76%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.33%
H: 1.54%
C: 0.19%
treatment phase 2 results als
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
TCON | $1.895 2.43% 2.37% 65K
|
Health Technology
|
| O: 2.95%
H: 1.11%
C: -6.05%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: 0.01%
H: 5.28%
C: 2.46%
phase 1 phase 3 phase 2
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
CLDX | $36.975 -2.11% -2.15% 390K
|
Health Technology
|
| O: 0.86%
H: 1.36%
C: -1.41%
ongoing phase 1 trial phase 3 phase 2
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
Published: 2021-06-04 (Crawled : 13:00) - globenewswire.com
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 3.74%
H: 3.11%
C: 2.76%
phase 1 phase 3 phase 2
Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia
Published: 2021-06-04 (Crawled : 12:15) - biospace.com/
VIRI | $0.436 1.16% 1.15% 200K
|
Health Technology
|
| O: 4.97%
H: 1.23%
C: -4.39%
phase 2 phase 2b fibromyalgia trial xin
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting
Published: 2021-06-04 (Crawled : 12:00) - globenewswire.com
FATE | News | $4.3 -5.29% -5.58% 2M
|
Health Technology
|
| O: 1.53%
H: 9.81%
C: 6.61%
phase 1 positive phase 3 phase 2 t-cell
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.